Viking Therapeutics (VKTX) Amortization of Deferred Charges (2021 - 2026)

Viking Therapeutics (VKTX) has 6 years of Amortization of Deferred Charges data on file, last reported at $85000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges fell 23.42% year-over-year to $85000.0; the trailing twelve-month figure through Mar 2026 stood at $405000.0 (up 5.74% YoY), and the FY2025 full-year result was $431000.0, up 24.57% from the prior year.
• Amortization of Deferred Charges eased to $85000.0 in Q1 2026, from $94000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $142000.0 in Q3 2022 to a low of $72000.0 in Q4 2022.
• A 5-year average of $90312.5 and a median of $81000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges surged 89.33% in 2022 and slumped 48.59% in 2023, its largest moves.
• Tracing VKTX's Amortization of Deferred Charges over 5 years: stood at $72000.0 in 2022, then advanced by 2.78% to $74000.0 in 2023, then surged by 48.65% to $110000.0 in 2024, then dropped by 14.55% to $94000.0 in 2025, then slipped by 9.57% to $85000.0 in 2026.
• Business Quant data shows VKTX's Amortization of Deferred Charges at $85000.0 in Q1 2026, $94000.0 in Q4 2025, and $114000.0 in Q3 2025.